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ABSTRACT 
Tumor Necrosis Factor-α Converting Enzyme (TACE) induces active TNFα and 
may contribute to the development of colitis in humans.  I hypothesized that 
pharmacological blockade of TNFα production would improve colitis scoring through 
decreased expression of inflammatory biomarkers.  Acute colitis was induced in wild 
type BALB/c mice using 5% dextran sulfate sodium (DSS) in drinking water for 7 days.  
TACE inhibition was accomplished through twice daily intraperitoneal injection of DPC-
333 (10mg/kg; BSM Inc.) To determine the effects of TACE blockade during colitis, the 
following experimental groups (n=6-7/group) were tested: 1) vehicle; 2) DPC-333; 3) 5% 
DSS and vehicle; and 4) 5% DSS and DPC-333. Twice daily TACE inhibition did not 
significantly improve overall colitis scoring index as determined by the presence of 
diarrhea, rectal bleeding, and percent weight loss. TNFα, IL-6, Il-1β, IL-10, and MPO in 
regional colon tissue were not reduced following DPC-333 in this model (p<0.05). Thus, 
TACE inhibition does not appear to reduce colitis scoring, TNFα production, or other 
regional biomarkers of inflammation in this model of experimental colitis.  Future studies 
may ascertain the role of TACE during systemic inflammatory diseases. 
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INTRODUCTION 
 
Clinical Inflammatory Bowel Disease 
Overview of Inflammatory Bowel Disease.  Inflammatory bowel diseases 
(IBDs) are chronic conditions characterized by relapsing events of aberrant inflammation 
in the gastrointestinal tract and gut-associated organs.  The two most prevalent IBDs are 
Crohn’s Disease (CD) and Ulcerative Colitis (UC). As reported by the Centers for 
Disease Control and Prevention,  CD and UC occur in 201 and 238 adults per 100,000 in 
the United States (Kappelman et al., 2007). In 2008, the mean cost of IBD treatment was 
reported as $8265 per year for CD patients and $5066 per for UC patients, and IBD-
associated treatment costs in the United States were estimated at 6.3 billion dollars 
(Kappelman et al., 2008).  
Current pharmaceutical treatments of IBD are limited by efficacy and cost, and 
colectomy has been reported to occur in 13.0-16.5% of UC patents at 20 years after 
diagnosis (Targownik et al., 2012).  Surgical management of UC often results in required 
use of an ileostomy bag, and increases risk for complications, which include sepsis, 
fistula formation, rectal cancer, intra-abdominal bleeding, and death (Tulchinsky et al., 
2003). Severity of UC inflammation is a predictor of neoplasm formation in the colon, 
and reduction of inflammation may improve oncogenic effects of the condition (Rutter et 
al., 2004).  Ongoing research characterizing inflammatory signaling in animal models and 
identifying novel therapeutic targets is necessary to improve UC patient outcome.  
Signs and Symptoms of IBD.  CD and UC present with some similar signs and 
symptoms, including abdominal pain and cramping, diarrhea, gastrointestinal (GI) 
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bleeding, and weight loss. Differences between CD and UC include location of lesions 
along the GI tract and their depth within the intestinal wall. Sites of inflammation in CD 
can occur at any location along the GI tract, most often at the terminal ileum and 
proximal colon (Gore et al., 1996). Aphthoid ulcers are indicative of CD, and present in 
small, discrete formations, often penetrating transmurally across the intestinal wall 
(Simpkins, 1977).   
In contrast, ulceration in UC tends to be more diffuse than CD, with more 
continuous patches of inflammation effecting the mucosa of the rectum and colon (Gore 
et al., 1996).  Although not universal, UC generally begins from the rectum and 
progresses to more proximal regions of the colon, in a diffuse and continuous pattern 
(D’Haens et al., 1997). Compared to CD, UC presents discontinuous lesions less often, 
but these skip-lesions are routinely associated with the appendiceal orifice (D’Haens et 
al., 1997).  Severe conditions of UC may result in ulcers with observable transmural 
inflammation.  
Diagnosis of Clinical IBD.  In addition to patient-reported symptoms, IBD 
disease activity assessment for diagnosis and disease monitoring is accomplished 
primarily through radiographic and endoscopic evaluation of colon mucosa.  Endoscopy 
of the colon, or colonoscopy, accompanied with tissue biopsy allows for histological 
evaluation of the colon mucosa to be performed, an important step in differentiating IBD 
colitis from CD and other non-inflammatory colitis conditions such as toxic megacolon, 
infectious colitis, ischemic colitis, and radiation colitis (Leighton et al., Standards of 
Practice Committee, American Society for Gastrointestinal Endoscopy, 2006). Secondary 
diagnostic tools also improve diagnosis of inflammatory UC, such as laboratory 
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biomarkers found to correlate with leukocyte migration into the bowel lumen, including 
C-reactive protein and calprotectin (Schoepfer et al., 2013).  
Following assessment of the patient and determination that an acute flare-up of 
inflammatory colitis is occurring, pharmacological management begins. Disease 
assessment dictates which pharmacologic approach to utilize, as primarily determined by 
two general parameters: anatomical location of UC inflammation and assessment of 
inflammatory severity. In 2010, the Practice Parameters Committee of the American 
College of Gastroenterology (ACG) released UC practice guidelines for diagnosis and 
treatment of adult UC (Kornbluth et al., 2010). The guidelines establish classification of 
UC severity: mild, moderate, or severe.  These classifications were determined using 
Truelove-Witts disease activity scoring parameters, first established in 1954 for 
evaluation of corticosteroid treatment of UC (Truelove and Witts, 1954).  According to 
ACG, UC disease severity can be determined according to stool frequency, presence of 
blood in the stool, erythrocyte sedimentation rate, and signs of toxicity such as fever, 
tachycardia, or anemia.  Progression of UC beyond the distal colon (i.e. more proximal 
than the descending colon) increases likelihood of steroid-resistance and worsened 
prognosis, including increased rates of surgery and neoplasia (Etchevers et al., 2009).  
Therefore, some conditions of UC are categorized as “distal colitis” or “left-sided 
colitis.”  
Current Pharmacological Treatments of Ulcerative Colitis.  Current medical 
treatments for UC attempt to avoid surgical intervention by reducing inflammation at the 
primary site of tissue injury. Multiple pharmaceutical approaches are available for 
clinicians and patients, and specific benefits and obstacles dictate their administration on 
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a patient-by-patient basis. These options are represented by the drug families of 
aminosalicylates, corticosteroids, thiopurines, antibiotics, cyclosporine (CsA), and 
anti-TNFα treatment.  
Mesalamine belongs to the aminosalicylate family, and is also referred to as 
mesalazine or 5-aminosalicylic acid (5-ASA).  Oral administration of sulfasalazine, a 
prodrug for mesalamine, allows for targeted delivery of mesalamine to the large intestine 
(Azad Khan et al., 1977).  Sulfasalazine reaches the colon and is reduced to 5-ASA, at 
least in part by intestinal bacteria (Peppercorn and Goldman, 1972)   Other formulations 
of pro-mesalamine have been developed in order to reduce side effects.  Safety of the 
various aminosalicylate pharmaceuticals is currently being debated in the literature, with 
concern of nephrotoxicity and GI side effects such as abdominal pain, nausea, and 
diarrhea (Böhm and Kruis, 2014). 
Corticosteroids can be administered either orally or topically, by enema or foam. 
Corticosteroid treatment is primarily used to control acute colitis.  Although systemic 
corticosteroids are efficacious, some patients respond to treatment with steroid 
dependency, regarded as “medical treatment failure,” and surgical management will often 
occur (Munkholm et al., 1994). Adverse effects of corticosteroids are substantial, and 
include cosmetic effects such as weight gain, cataracts, osteoporosis, myopathy, and 
susceptibility to infections (Lichtenstein et al., 2006). These side effects limit the duration 
of their use, and steroid dependent colitis remission is considered treatment failure 
(Benchimol et al., 2008).   
Mercaptopurine (6-MP) is a thiopurine used in UC treatment. Azathioprine, a 
6-MP prodrug, is effective in inducing remission for steroid dependent UC patients 
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(Ardizzone et al., 2006).  The benefit of this treatment is primarily for steroid-dependent 
UC patients.  The steroid sparing effect may result in subsequent avoidance of a surgical 
resolution. Despite the steroid sparing benefit, acute UC management is difficult with 
thiopurine treatment because of delayed time until optimal effect, which can be greater 
than four months (Present et al., 1980).  
Cyclosporine (CsA) therapy was reported in 1994 as an effective non-surgical 
approach to treatment of corticosteroid-resistant UC (Lichtiger et al., 1994). CsA acts as 
an immunosuppressant by inhibiting calcineurin, a protein phosphatase. Calcineurin plays 
an integral role in T-cell development, and inhibition of calcineurin by CsA blocks T-cell 
function (Bram et al.,1993).  CsA treatment carries serious adverse effects, and can 
damage the renal system and increase risk of malignancy (Grossman et al., 1996).  
Because of the adverse effects, CsA treatment is reserved for severe acute colitis, when 
medical urgency to reduce inflammation and prevent colectomy is apparent.  
Tumor necrosis factor-α (TNFα) is a proinflammatory cytokine involved in 
inflammatory colitis.  Infliximab is a monoclonal antibody administered via intravenous 
infusion, and is the current standard in anti-TNFα approaches to UC treatment. 
Anti-TNFα treatment is the most recent advancement in pharmaceutical approach to IBD 
management.  In mild-moderate colitis, Infliximab is effective in resolving acute 
inflammation flare-up and improving remission time (Rutgeerts et al., 2005). Response to 
treatment may be hindered by development of antibodies against Infliximab by the 
patient, resulting in undetectable levels of Infliximab in the serum (Baert et al., 2003).  
Additionally, development of antibodies increases risk of reaction to Infliximab 
infusions.  
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Current Medical Guidelines of UC Treatment.  For mild to moderate left-sided 
UC, the preferred treatment option is topical mesalamine administered by enema, 
although oral aminosalicylate or topical steroids are also effective (Cohen et al., 2000). 
While most patients respond to these treatments, oral corticosteroids or Infliximab may 
be required if the condition does not improve.   
Extensive UC is a condition of inflammation progression proximal to the left colic 
flexure.  For these patients, topical treatments such as enema, foams, and suppositories 
lose efficacy because of an inability to reach sites of injury (Kornbluth and Sachar, 2010). 
Oral sulfasalazine (or other mesalamine prodrug variations) have become the gold 
standard for extensive UC ever since its clinical studies were performed in the 1960s 
(Dick et al., 1964).  Resistance to initial treatment in extensive UC is more common than 
left-sided UC.  As a result, a variety of treatment options are practiced for patients who 
are unresponsive to sulfasalazine treatment or unable to tolerate the side effects. Oral 
administration of corticosteroids may be effective in these cases (Baron et al., 1962). 
Steroid approach may also be appropriate if there appears to be medical urgency in 
improvement (Kornbluth et al., 2010).  If complete resolution of disease is not 
accomplished with corticosteroids, thiopurines may be administered. Following 
thiopurine treatment, Infliximab infusion may be necessary for steroid-refractory and 
steroid-dependent patients.  
Acute severe UC also presents with increased incidence of steroid resistance and 
colectomy.  Treatment guidelines for acute severe colitis dictate intravenous steroids such 
as methylprednisolone for 7 to 10 days. If the patient does not respond to steroid 
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treatment, rescue therapy with CsA or Infliximab occurs, and colectomy occurs with 
inadequate response (Fig. 1).   
 
 
Figure 1. Methods of Medical Rescue Therapy for Severe Acute Ulcerative Colitis.  
Medical rescue therapies used in patients after failure of response to intravenous steroids 
include cyclosporine or inhibition of tumor necrosis factor with Infliximab.  Inadequate 
response to rescue therapy is resolved with colectomy (Kedia et al., 2014).   
 
Quick acting, long-term treatments aimed at increasing remission time and 
reducing flare-ups are necessary in treating inflammatory colitis. Steroid-sparing 
treatments, such as anti-TNFα treatments, may provide long-term solutions to IBD 
management.  Current anti-TNFα treatments are primarily last-resort medical approaches 
to steroid and thiopurine resistant IBD patients, and patients not responding to these 
therapies will undergo colectomy (Nelson el al., 2014). Novel methods of TNFα 
inhibition in UC may increase patient response to treatment, decrease cost of 
manufacture, and decrease side effects. Through alternative methods of TNFα inhibition, 
a more universal treatment approach to inflammatory colitis may be possible.  
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Tumor Necrosis Factor-α and Inflammatory Signaling 
Tumor Necrosis Factor-α.  In 1975, while researching inhibitory effects of 
bacterial products on human cancer, Carswell et al. demonstrated endotoxin-induced 
necrosis of tumor cells required a host-derived mediator (Carswell et al., 1975). This 
factor was deemed tumor necrosis factor (TNF).  TNF was originally observed in its 
soluble isoform, and in 1988, the membrane-bound precursor of TNF was observed 
(Kriegler et al., 1988).  Pro-TNF is cleaved and activated by a metalloprotease, shedding 
the soluble ectodomain of TNF from the cell surface (McGeehan et al., 1994).  The 
protein responsible for TNFα activation, TNFα converting enzyme (TACE), was isolated 
and identified in 1997 (Moss et al., 1997).  Since its identification, TNFα has been 
implicated as a master regulator of inflammation, and novel methods of disease treatment 
through TNFα reduction are continuously being explored (Fig. 2).  
The physiological role of TNFα and its ability to drive the inflammatory response 
is important for the body’s defense against invading pathogens.  As a result, current use 
of anti-TNFα approaches in treating pathological inflammation impart an increased risk 
of infection, particularly from latent infections such as with M. tuberculosis and 
opportunistic infections such as with C. difficile (Ali et al., 2013). Additionally, anti-
TNFα treatment approaches are withheld during active infection by a variety of 
pathogens including bacterial, fungal, viral, and parasitic. TNFα driven inflammation 
produces a rigorous defense mechanism against pathogens, however, this protection 
comes at a cost.  Pathological inflammatory conditions, such as during the development 
of sepsis, produce elevated levels of TNFα, IL-1β, and IL-6 and result in excess tissue 
damage and impairment of organ function in response to infection (Munoz et al., 1991). 
9 
 
Figure 2. Activation and Inhibition of Tumor Necrosis Factor (TNF) and TNF receptor 
(TNFR).  Membrane-bound proTNF is cleaved by TNF alpha converting enzyme 
(TACE) to release soluble TNF (sTNF).  Current pharmaceuticals for inhibiting TNFR1/2 
activation are monoclonal antibodies (Infliximab/adalimumab) and the fusion protein 
Etanercept.  Reduction in sTNF through TACE inhibition and effects on inflammatory 
pathology is currently being investigated (Moss et al., 2008).   
 
Other physiological roles of TNFα may not be primarily to initiate an 
inflammatory response. For example, acute vigorous exercise increases circulating levels 
of TNFα, without increasing expression of TNFα mRNA (Bernecker et al., 2013).  In the 
central nervous system, TNFα is involved in a number of neurodegenerative and 
pathological conditions such as multiple sclerosis and Alzheimer’s disease (Kruglov et 
al., 2011).  However, TNFα is also promotes oligodendrocyte proliferation and 
re-myelination of neurons (Arnett et al., 2001).  Additionally, TNFα is involved in 
maintaining neuronal cell survival and modulation of neuronal pathways during the 
proper development of the nervous system (Davies, 2003).  
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Physiological levels of circulating TNFα vary widely, and are impacted 
significantly with increased age.  One study found circulating TNFα in healthy adults to 
range from < 1 pg/mL to 10 ng/mL (Mózes et al., 2011).  Besides variation due to age, 
circulating TNFα levels may follow a circadian pattern, as TNFα stimulates the release of 
corticotropin-releasing hormone and activation of the hypothalamic-pituitary-adrenal axis 
and corticosterone secretion (Bernardini et al., 1990).   
TNFα and Receptor Families: Structure and Biology.  TNFα is a member of 
the TNF superfamily (TNFSF), the largest known family of cytokines, and TNF ligands 
activate corresponding transmembrane receptors of the TNF receptor superfamily 
(TNFRSF) superfamily. As of December 2011, 18 TNFSF and 29 TNFRSF genes have 
been identified in humans (Wiens and Glenney, 2011).  The TNF homology domain is 
conserved across the TNFSF ligands, and interacts with cysteine-rich domains of the 
TNFRSF receptors (Bodmer et al., 2002).   
In general, activation of TNFRSF members result in two opposing signal 
transduction pathways: cell death via apoptosis and necrosis or pro-inflammatory cell 
survival (Dempsey et al., 2003). Cell death signaling is induced by TNFR death domains, 
while cell survival and inflammation results from receptor interaction with TNF receptor 
associated factor (TRAF) proteins. The survival or death result of ligand binding is 
dependent on the presence of the death domain in the receptor and affinity of the receptor 
to intracellular signaling proteins promoting either cell death or inflammation (Dempsey 
et al., 2003). Two TNFRs have been identified for TNFα interaction and activation, 
TNFR1 (TNFRSF1A, CD120a, and p55) and TNFR 2 (TNFRSF1B, CD120b, and p75) 
(Brockhaus et al., 1990). 
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TNFα is initially expressed as a 26kDa homotrimeric type II transmembrane 
protein (mTNFα) (Kriegler et al., 1988).  Upon cell stimulation, the extracellular domain 
of mTNFα is cleaved into a 17kDa soluble isoform (sTNFα) by TNFα converting enzyme 
(TACE), a disintegrin and metalloproteinase (ADAM) protein, specifically ADAM17 
(Black et al., 1997). Both mTNFα and sTNFα are biologically active, and promote 
different signal transduction through TNFR1/2 activation (see below).  
TNFα Receptors.  TNFR1 and TNFR2 bind soluble and membrane-bound TNFα 
(Locksley et al., 2001). TNFR1/2 contain hydrophobic cysteine-rich repeats, which form 
a pre–ligand binding assembly domain (PLAD), resulting in trimerization of the receptors 
in the absence of TNFα activation (Chan et al., 2000). TNFR activity is not exclusively 
pro-inflammatory, as TNFR1 and TNFR2 extracellular domains are cleaved into soluble 
TNFR1/2, and act to attenuate the inflammatory response by sequestering sTNFα 
(Wallach et al., 1991). For example, mutations in the TNFR1 extracellular domain can 
prevent shedding and result in autosomal dominant periodic fever syndrome, 
characterized by relapsing episodes of localized inflammation and fever (McDermott et 
al., 1999). TNFR2 is primarily expressed in immune cells and TNFR1 expression is 
mostly ubiquitous across cell types. While TNFR1 is fully activated by sTNFα, TNFR2 is 
primarily activated by mTNFα and is not fully activated by sTNFα (Grell et al., 1995). 
TNFR1 Signaling.  TNFR1 activation is capable of activating either cell survival 
signaling or cell death.  Survival and pro-inflammatory signal transduction occurs 
through activation of the transcription factor, nuclear factor kappa B (NF-κB) (Fig. 3).   
Production of TNFα and other inflammatory cytokines is activated by NF-κB.  NF-κB is 
sequestered to the cytoplasm by inhibitor of kappa B protein (IκB) through masking of 
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NF-κB’s nuclear localization signal. Inflammatory stimulation of the cell activates a IκB 
kinase (IKK) complex, which phosphorylates the regulatory domain of IκB (Mercurio et 
al., 1997).  This phosphorylation marks IκB for recognition by E3 ubiquitin ligase and 
subsequent degradation.  With its nuclear localization signal exposed, NF-κB translocates 
to the nucleus where it interacts with κB response elements. 
 
 
Figure 3. Tumor Necrosis Factor Receptor 1 Signaling.  Proinflammatory  signaling from 
TNF activation of TNFR1 results in translocation of Nuclear Factor-kB (NF-kB) to the 
nucleus.  The receptor complex (complex-I) consists of TNFR-associated via death 
domain (TRADD), RIPK1, TNFR-associated factor 2 (TRAF2) and cellular inhibitor of 
apoptosis 1 (cIAP1).  Complex I activates linear ubiquitin chain assembly complex 
(LUBAC) and ubiquitin (Ub) chains are attached to IkB kinase (IKK) proteins. The 
activated IKK complex phosphorylates inhibitor of kappa B (IkB/NFkBIA), resulting in 
IkB degradation.  Degradation of IkB exposes the nuclear localization signal contained in 
NF-kB, and translocation to the nucleus occurs.  TNFR1 activation by TNF is also 
capable of initiating apoptosis, determined by the presence of pro-survival cIAPs and NF-
kB transcriptional products (Gyrd-Hansen and Meier, 2010).   
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Signal transduction  from TNFR1 is initiated by its intracellular death domain 
(DD), which shares critical amino acid residues with the Fas receptor (Tartaglia et al., 
1993).  The DDs of self-associated mTNFR1 complexes are capable of NF-κB activation, 
independent of ligand presence.  However, a silencer of death domain (SODD) protein 
associates with TNFR1 and masks the DD, preventing recruitment of signaling proteins 
(Jiang et al., 1999).  TNFα activation n of TNFR1 results in SODD dissociation and 
recruitment of TNFR1-associated death domain protein (TRADD) (Fig. 3) (Hsu et al., 
1995). The TRADD-TNFR1 complex serves to scaffold the association of TNFR 
associated factors 1 and 2 (TRAF1/2) and receptor-interacting kinase (RIP), a serine-
threonine kinase (Hsu et al., 1996). The TRAF protein family also interacts with pro-
inflammatory receptors IL-1 receptor (IL-1R) and  toll-like receptors (TLRs) (Wajant et 
al., 2001).  
TNFR1 activation of IKK requires both TRAF2 and RIP. TRAF2 is essential in 
recruitment of IKK to the activated receptor complex, and RIP is essential in IKK 
activation (Devin et al., 2000). RIP mediated activation of NF-κB may also be indirect, as 
inhibition of the mitogen-activated protein kinase (MAPK) pathway attenuates NF-κB 
activity (Yang et al., 2001). TRAF also scaffolds the receptor to regulators of MAPK 
signaling pathway, therefore inducing cell survival signal transduction.  
NF-κB activation requires receptor-associated TRAF1/2 recruitment of inhibitor 
of apoptosis protein (IAP) (Fig. 3) (Rothe et al., 1995). IAP proteins are essential for RIP 
ubiquitinaton (Varfolomeev et al., 2008) and RIP poly-ubiquitinaton at Lys-377 is 
required for IKK activation (Ea et al., 2006).  A linear ubiquitin chain assembly complex 
(LUBAC) is responsible for attaching ubiquitin chains to RIP and also IKK (Haas et al., 
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2009). IKK is recruited to the protein complex through interaction of the polyubiquitin 
chains and the IKK regulatory subunit, NF-kappa-B essential modulator (NEMO), also 
known as inhibitor of nuclear factor kappa-B kinase subunit gamma (IKK-γ) (Ea et al., 
2006).   
After recruitment to the receptor, IKK phosphorylates IκB.  Phosphorylated IκB is 
ubiquitinated by beta-transducin repeat containing protein (βTrCP1), an E3 ubiquitin 
ligase (Fig. 3) (Kanarek et al., 2010).  Ubiquitinated IκB is degraded through the 
ubiquitin-proteasome pathway. Degradation of IκB exposes the nuclear localization 
signal of NF-κB, allowing it to translocate to the nucleus.  
Transcriptional activity of NF-κB promotes expression of anti-apoptotic genes, 
including TRAF1/2 and IAPs, which act to block caspase-8 activation and apoptosis 
initiation (Wang et al., 1998).  Regulation of NF-κB transcriptional activity is achieved in 
part through autoregulation by NF-κB –inducible gene expression. For example, NF-κB 
activation increases protein A20 expression, an inhibitor of TRAF2 and NF-κB activation 
(Song et al., 1996).   
TNFR2 Signaling.  TNFR2 does not contain a death domain, and is fully 
activated by mTNFα (Grell et al., 1995).  TNFα binding to TNFR2 recruits TRAF 
proteins to the receptor, and these TRAF proteins recruit IAP proteins to form a receptor 
complex similar to TNFR1 (Rothe et al., 1995). Similar to TNFR1, formation of the 
TNFR2 complex promotes cell survival and inflammation through activation of MAP 
kinase pathways and nuclear translocation of  NF-κB (Marchetti et al., 2004).   However, 
the TRAF proteins associated with TNFR2 may be capable of inducing two different NF-
κB pathways: canonical (traditional) and noncanonical (alternative) (Rauert H. et al., 
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2010) .  Both pathways induce translocation of cytoplasmic NF-κB to the nucleus.  
However, the alternative pathway activates a NF-κB-inducing kinase (NIK) mediator to 
generate free cytoplasmic NF-κB from an inhibitory precursor (Fig. 4).   
 
 
Figure 4. Canonical and Alternative NF-kB Activation Pathways.  Activation of 
TNFR1/2 primarily results in NF-kB (RelA-p50) translocation to the nucleus through 
proteasomal degradation of Inhibitor of kB (IkB) and exposure of the nuclear localization 
signal within NF-kB. TNFR2 may also activate the alternative NF-kB pathway, through 
activation of NF-κB–inducing kinase (NIK) and processing of p100.  Cleavage of p100 
results in a p52 NF-kB subunit, which translocates to the nucleus (Lawrence, 2009).   
 
The nk-kb2 gene produces a larger p100 protein, which acts to sequester NF-κB to 
the cytosol, similar to the traditional IκB proteins.  NIK action on the p100 protein results 
in ubiquitylation and proteasome-mediated cleavage of p100 into a p52 protein, a subunit 
of the NF-κB heterodimer (Coope et al., 2002). In this fashion the p100 protein acts as 
both an inhibitor of NF-κB activity and an NF-κB precursor within the alternative NF-κB 
pathway.  
16 
Signaling cascades initiated through TNFR2 activation are less characterized than 
its TNFR1 counterpart. For example, TNFR2 activates serine-threonine and tyrosine 
kinases.  However, the resulting effects are still unknown.  sTNFR2 is shed by TACE, 
and mutation of the catalytic domain in TACE results in decreased shedding of both 
sTNFα and sTNFR2 (Solomon et al., 1999).  Importantly, sTNFR2 has been found to 
retain its biological activity and interact with sTNF, resulting in formation of inactive 
TNFα-TNFR2 complexes (Balcewicz-Sablinska et al., 1998).   
The ability of sTNFR2 to sequester sTNFα has been utilized pharmacologically 
with the development of Etanercept, a fusion protein produced with the TNFR2 
extracellular receptor-binding domain and immunoglobulin G regions (Fig. 2) (Peppel et 
al., 1991).  Etanercept gained FDA approval in 1998 for treatment of rheumatoid arthritis 
(CDER, 2009).  However, clinical trials of Etanercept in IBD have shown poor efficacy 
(Sandborn et al., 2001).  Although Etanercept and Infliximab are both effective in 
reducing free TNFα, only Infliximab also interacts with and induces apoptosis of 
activated leukocytes (Van den Brande et al., 2003).  In addition, administration of 
Etanercept in treatment of rheumatoid arthritis has been associated with inducing IBD, 
although this effect requires further investigation (Oh et al., 2005).  Current applications 
of Etanercept administration are limited. In 2008 the FDA updated the package insert for 
Etanercept with a “black box” warning of the increased risk of infection associated with 
its administration. As a result of safety issues and lack of efficacy with Etanercept, the 
standard anti-TNFα approach to treatment of IBD is Infliximab.  
Cell Survival or Death.  TNFR1 activation results in formation of two different 
signaling complexes, complex I and complex II, also known as death-inducing signaling 
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complex (DISK) (Fig. 3) (Micheau and Tschopp, 2003). Complex I activates the NF-κB 
pathway, resulting in pro-inflammatory and cell-survival gene expression, and is 
comprised of TRADD, RIP, TRAF2, and c-IAP1 (Micheau and Tschopp, 2003). The 
second complex, complex II, initiates apoptosis via interactions of TNFR1’s death 
domain and procaspases 8 and 10.  
Complex II localizes within the cytosolic compartment of the cell, indicating 
dissociation from TNFR1. In contrast, complex I isolation experiments show it is 
associated with the cell membrane (Micheau and Tschopp, 2003).  A balance between 
cell survival with pro-inflammatory cytokine expression or cell death is accomplished 
through these signaling systems and is determined by a complex system of input 
parameters, including cell type, location, and ligand activation of the cell. This system 
allows for spacial and temporal regulation of the cellular response to stress.  
Molecular Roles in Inflammatory UC.  NF-κB translocation to the nucleus 
results in transcription of proinflammatory cytokines IL-6 and IL-1β (Hiscott et al., 1993; 
Libermann and Baltimore, 1990).  IBD pathology presents with increased IL-6 
expression in the intestinal tissue, which promotes survival of inflammatory T cells and 
stimulates additional inflammatory signaling (Mudter and Neurath, 2007).  IL-1β is also 
elevated in the plasma and colonic tissues of IBD patients (Ludwiczek et al., 2004).  
Additionally, NF-κB activation induces TNFα transcription (Collart et al., 1990).   
Inflammatory activation of NF-κB promotes the positive feedback nature of the 
inflammatory response through transcription of additional proinflammatory cytokines. 
IL-10 is an anti-inflammatory cytokine, and mutations in the IL-10 receptor have 
been observed in patients with early-onset inflammatory enterocolitis (Glocker et al., 
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2009).  Expression of IL-10 decreases transcription of inflammatory cytokines, 
independent of NF-κB activation (Murray, 2005).  IL-10 activates signal transducer and 
activator of transcription 3 (STAT3), which indirectly reduces cytokine transcription by 
promoting transcription of cytokine transcription regulators (Murray, 2005).  IL-10 
expression is also induced by NF-κB activation (Cao et al., 2006), although numerous 
other transcription factors also regulate IL-10 expression, such as cAMP-responsive-
element-binding protein (CREB), musculoaponeurotic fibrosarcoma oncogene homolog 
(Maf), and c-jun (Saraiva and O’Garra, 2010). 
 
Tumor Necrosis Factor-α Converting Enzyme 
A Disintegrin and Metalloprotease Proteins.  The zinc protease superfamily is a 
broad group of enzymes requiring zinc interaction for activation of the catalytic site.  The 
member families are classified according to the primary sequence of the catalytic site, 
and include gluzincin, metzincin, inverzincin, carboxypeptidase, and DD-
carboxypeptidase families (Hooper, 1994).  Metzincins contain a methionine amino acid 
adjacent to the zinc active site in a “Met-turn” motif, and include serralysin, astacin, 
matrixin, and adamalysin subgroups (Stöcker et al., 1995). The adamalysins are proteins 
containing metalloprotease and disintegrin domains, and ADAM proteins (a disentigrin 
and metalloprotease) are a subtype of adamalysins (Fig. 5).  There are 21 known ADAM 
genes in humans, 13 with functional protease activity (Edwards et al., 2008).  
Localization of mature ADAM proteins to the membrane is achieved with the 
secretory pathway, from the rough endoplasmic reticulum, through the Golgi, and then 
incorporation into the plasma membrane (Lum et al., 1998). ADAM proteins are 
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expressed with a prodomain that inhibits the metalloprotease activity.  A “cysteine-
switch” maintains inactivity through interaction of a prodomain cysteine residue and the 
essential zinc ion in the catalytic site (Van Wart and Birkedal-Hansen, 1990). Removal of 
the inhibitory prodomain primarily occurs in the Golgi, by pro-protein convertase 
enzymes, resulting in predominately active forms of membrane-bound ADAM proteins 
(Lum et al., 1998).  
 
 
Figure 5.  Functional Domains of A Disintegrin and Metalloprotease (ADAM) and 
Related Proteins.  TACE (ADAM17) and the other ADAM proteins share domains with 
Matrix Metalloproteases (MMPs), Snake Venom-MMPs (SV-MMP), and 
Thrombospondin-like ADAM (ADAM-TS) proteins.  ADAM proteins are directed to the 
plasma membrane with a signal sequence and anchored by a transmembrane domain.  
The prodomain regulates activation of the catalytic site within the metalloprotease 
domain.  The disintegrin domain is known to interact with integrin receptors.  The 
cysteine-rich and EGF-like domains may facilitate substrate interaction (Seals and 
Courtneidge, 2003).  
  
The defining features of the ADAM proteins are its namesake metalloprotease 
and disintegrin domains. The metalloprotease domain contains the proteolytic active site. 
This site contains zinc atoms and water molecules essential for protein hydrolysis 
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(Maskos et al., 1998). Three histidine residues and the Met-turn coordinates the cofactors 
and substrate for cleavage.   
The disintegrin domain is named after its activity in another adamalysin protein, 
snake venom metalloproteases (SVMPs), found in viper snake venom (Gutiérrez et al., 
2005). These proteins block platelet aggregation and thrombus formation through 
interaction with platelet integrin receptors, resulting in hemorrhage (Huanget al., 1987). 
For human ADAM proteins, the type and function of integrin interaction is varied and 
poorly understood.  Specific cell type and individual ADAM proteins determine integrin 
interaction and produce different cell adhesion and mobility effects (Cal et al., 2000; 
Nath et al., 2000; Zhang et al., 1998). 
 
TACE Biology 
The enzyme responsible for shedding soluble TNFα from the plasma membrane is 
ADAM17, commonly referred to as tumor necrosis factor-α converting enzyme (TACE) 
(McGeehan et al., 1994; Moss et al., 1997). The critical role of TACE in inflammatory 
signaling was highlighted in a study of mice with cleavage-defective mTNFα (Ruuls et 
al., 2001).  These mice displayed attenuated inflammatory responses, similar to TNFα 
knockout mice, indicating that mTNFα shedding is essential to propagation of 
inflammatory signaling.  Manipulating sTNFα levels through TACE inhibition allows for 
modulation of inflammatory response to stimulus, and TACE inhibition improves 
survival of mice against a lethal dose of the endotoxin lipopolysaccharide (Mohler et al., 
1994).   
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In addition to its pivotal role during inflammation, the complete biological role of 
TACE is surprisingly complex. This was first observed in mice with non-functioning 
TACE, where TACE disruption limited the viability of most mice to the embryonic stage 
or to a few days of age (Peschon et al., 1998).  Mice without TACE activity were born 
with stunted vibrissae (whiskers) and open eyelids (mice are usually born with closed 
eyelids), as a result of failed eyelid fusion. A small number of mice survived for several 
weeks.   However, they displayed reduced bodyweight, disrupted eye development, and 
abnormal hair follicle structure and function.  Defects in proper development of epithelial 
tissues and therefore digestive, respiratory, and hormonal systems were observed.   
Peschon et al. also observed cells without functional TACE activity displayed 
reduced TNFR2, L-selectin, and transforming growth factor-α (TGFα).  The phenotypes 
of the TACE-defective fetuses were similar to TGFα knockout mice (Sibilia and Wagner, 
1995), thereby implicating TACE as a sheddase for TGFα and critical to embryologic 
development. Over thirty TACE substrates have since been identified, with involvement 
in development (TGFα), neuroprotective protein clearance (amyloid precursor protein), 
inflammation (TNFα, TNFR1/2, IL6R), and tumor development and proliferation (EGF, 
TGFα, CD44) (Pruessmeyer and Ludwig, 2009).  
TACE Activity during Inflammatory Pathology.  Aberrant TACE activity has 
been observed in a variety of inflammatory disorders. Rheumatoid arthritis patients have 
increased cartilage TACE mRNA levels (Patel et al., 1998), and chondrocyte expression 
(Amin, 1999). Peripheral monocyte expression of TACE is increased in patients with 
early systemic sclerosis (Bohgaki et al., 2005).  Psoriasis patients experience increased 
TACE mRNA expression in keratinocytes, endothelium, and mast cells contained within 
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the psoriatic lesions (Kawaguchi et al.,  2005). Staphylococcus aureus and Pseudomonas 
aeruginosa stimulate TACE transcription of lung epithelial cells (Gómez et al., 2005). 
TACE is also involved in IBD pathologies.  Cell membrane detergent extracts of 
UC patients display increased TNFα cleavage potential, indicating increased functional 
TACE capacity (Brynskov et al., 2002). Biopsies of inflammatory lesions of intestinal 
epithelia in CD patients showed increased TACE expression, during the early 
development of and active CD lesions (Cesaro et al., 2009). Regulation of TNFα levels 
through TACE inhibition may prove to be a viable method of disease treatment and 
maintenance of remission in IBD.  
History of TACE Inhibition and DPC-333.  A common model of septic 
endotoxemia utilizes lipopolysaccharide (LPS), a component of the cell wall in gram 
negative bacteria.  After TACE inhibition was shown to protect mice against lethal LPS 
dosing, preclinical trials for TACE inhibition during inflammatory pathologies in animal 
models was explored (Mohler et al., 1994). Many of these early studies utilized intra-joint 
inflammatory models for rheumatoid arthritis, and later clinical trials in humans (Moss et 
al., 2008).  Despite early success in preclinical models, the furthest progression of a 
TACE inhibitor to-date is phase II of clinical trials for treatment of rheumatoid arthritis, 
where issues with liver toxicity and/or lack of efficacy ended the trials.  
There are four classes of ADAM metalloprotease inhibitors: denaturing inhibitors, 
Zn chelators, small molecule inhibitors, and tissue inhibitor of metalloproteinase proteins 
(TIMPS) (Moss et al., 2001).  The TACE-specific inhibitor DPC-333 [(2R)-2-((3R)-3-
Amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-
methylpentanamide)], is  a small molecule inhibitor invented in 2002 by Irma Benedek 
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and Michael Fossler and is owned by the Bristol-Myers Squibb Company (Fig. 6) 
(Benedek and Fossler, 2003).  Small molecule inhibitors have traditionally exhibited poor 
specificity, and resulted in broad inhibition of all proteins with metalloprotease domains, 
and inhibition of additional metalloprotease enzymes may have contributed to increased 
adverse effects during previous clinical trials (Moss et al., 2001).  
 
 
Figure 6. Chemical structure of DPC-333 (Qian et al., 2007) 
 
DPC-333 is largely considered a partially selective inhibitor of TACE (Bahia and 
Silakari, 2010; Moss et al., 2008), reported by Bristol-Meyers Squib (BMS) to have a 
dissociation constant (Ki) of 0.18 nM to TACE, and Ki of 2, 10, and 12 nM for MMP-12, 
ADAMTS-4, and MMP-3 (product sheet - BMS). Previously, DPC-333 has been 
evaluated in clinical trial for rheumatoid arthritis treatment, reaching phase II before liver 
toxicity issues resulted in discontinuation of the trial (Moss et al., 2008). 
Pharmacokinetics and pharmacodynamics data for DPC-333 in animals and 
humans were published in 2007 by Qian et al.  Orally administered DPC-333 is 
biologically active, and results in decreased plasma TNFα levels in the blood of mice and 
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humans.  The i.v. bolus dose of DPC-333 in mice had a half-life of approximately 1 hour. 
The mean systemic plasma clearance was 6.2 1/h/kg.  Mice have low oral bioavailability 
of less than 20%, but 98% after IP injection of 11mg/kg bodyweight. The free fraction of 
DPC is 2 to 3 times greater in rodents than in humans. IP injection of DPC-333 in mice is 
rapidly absorbed and maximum plasma concentration is reached at 0.1 hours after 
injection.  TNFα response to LPS challenge in mice is inhibited by IP DPC-333 in a dose-
dependent manner, with ED50 of 1.9 mg/kg dose. In this clinical safety trial, DPC-333 
was found to be safe and tolerated in humans. Adverse effects were reported in 53.3% of 
DPC-333 recipients (n=60) and 40% of the placebo group (n=20), with taste disturbance 
as the most commonly reported adverse experience.  
 
Neutrophil Recruitment and Myeloperoxidase  
A signature feature of the inflammatory response is chemotactic recruitment of 
polymorphonuclear leukocytes (neutrophils) and other leukocytes to the site of 
inflammatory stimulus (Ajuebor et al., 1999).  Constitutive expression of L-selectin on 
the surface of leukocytes supports neutrophil rolling and resulting emigration through the 
vessel endothelium (Smith, 1993).  Broad inhibition of metalloprotease activity and 
subsequent decreased L-selectin cleavage, has been observed to inhibit lymphocyte 
emigration across the capillary wall during inflammation (Faveeuw et al., 2001).  TACE 
has been identified as a sheddase of L-selectin in-vivo, and TACE-deficient neutrophils 
and other leukocytes expressed increased L-selectin on the cell membrane (Li et al., 
2006).  TACE inhibition during colitis may disrupt neutrophil emigration to the primary 
site of inflammation in the colon, decreasing inflammation.  
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Neutrophils are phagocytic leukocytes and utilize mechanisms of oxidative stress 
to destroy engulfed pathogens. Azurophilic granules within the neutrophil store the 
enzyme myeloperoxidase (MPO).  Pro-inflammatory signaling stimulates neutrophil 
degranulation and MPO activity (Schultz and Kaminker, 1962).  MPO activity increases 
the oxidative potential of hydrogen peroxide by generating hypochlorous acid and tyrosyl 
radicals (Heinecke, 1999).  Quantification of MPO levels in inflamed tissues and organs 
correlates to neutrophil recruitment and increased inflammatory conditions (Pulli et al., 
2013). 
 
A Colitis Mouse Model with Dextran Sulfate Sodium 
Model Overview.  A murine model of intestinal inflammation using the polymer 
dextran sulfate sodium (DSS) is an accepted method of investigating UC (Strober et al., 
2002).  Supplementing the animal’s drinking water for 7 days results in erosion of the 
colonic mucosa, dysplasia, shortening of the large intestine, diarrhea, gross rectal 
bleeding, and weight loss (Okayasu et al., 1990).  Although, the mechanism of DSS-
induced inflammation is not completely understood, mucosal barrier degradation during 
DSS-induced colitis may result from direct toxicity to the intestinal epithelia (Dieleman 
et al., 1994).  Severity of response to DSS is strain dependent, and C57BL/6 mice 
develop a more severe phenotype with less DSS than BALB/c mice (Melgar et al., 2005).  
The DSS colitis model is beneficial in studying inflammation due to rapid development 
of colitis, ease of administration, and dosing control (Wirtz et al., 2007).  Inhibition of 
TNFα with intraperitoneal injection of Infliximab during the development of DSS colitis 
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reduces disease activity index, histology scoring of mucosal degradation, and intestinal 
epithelial apoptosis (Qiu et al., 2011) 
The DSS induction of mucosal degradation occurs in the absence of T and B cell 
development (Dieleman et al., 1994).  Therefore, DSS colitis may be a poor model of 
investigating aspects of inflammation involved with cell-mediated adaptive responses.  
However, induction of NF-κB activity and production of inflammatory cytokines allows 
the DSS model of colitis to be a good investigatory tool in evaluating the innate immune 
response during inflammation and colitis.   
Cytokine and Neutrphil Response to DSS Colitis.  Concentrations of 
inflammatory cytokines IL1β, IL-6, and TNFα increase in the colon during development 
of DSS colitis (Dieleman et al., 1994).  After blood samples are allowed to clot for 30 
minutes, the serum of DSS colitis mice also show increased pro-inflammatory cytokine 
concentrations (Alex et al., 2009).  There is a larger increase of pro-inflammatory 
cytokines in the colon tissue of C57BL/6 than in BALB/c mice, corresponding to 
increased sensitivity of C57BL/6 mice to DSS (Melgar et al., 2005).  For C57BL/6 mice, 
expression of IL1β, IL-6, and TNFα mRNA in the colon increases in response to DSS 
treatment (Yan et al., 2009).  Increased TNFα mRNA predominately occurs in the 
proximal colon and IL-6 mRNA is more increased in the distal colon.   
IL-10 emerged as a key suppressive mediator of intestinal inflammation when 
IL-10 knockout mice were found to spontaneously develop chronic colitis (Kühn et al., 
1993).  In contrast, overexpression of IL-10 in chemical colitis mouse models attenuated 
disease activity and reduced proinflammatory markers, such as IL-1β and TNFα (Lindsay 
et al., 2002).  For DSS colitis models, high variability of IL-10 concentration has been 
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reported, dependent on strain type and duration of DSS treatment.  Increased serum IL-10 
concentration for chronic, but not acute DSS colitis in C57BL/6 mice has been reported 
(Alex et al., 2009).  In C57BL/6 mice, colon tissue IL-10 mRNA expression increases 
with DSS administration until day 5, and expression may become consistent (Yan et al., 
2009).  
Acute DSS models also produces increased MPO activity in the colon tissues, 
indicating increased neutrophil recruitment to the primary site of injury (Alex et al., 
2009).  This increase may primarily occur in the proximal colon (Yan et al., 2009).  An 
increase of MPO activity has been observed in the cecum and rectum of BALB/c mice 
after 7 days of 5% DSS treatment (Hamamoto et al., 1999). 
 
Hypothesis and Rationale 
My study will investigate the following hypotheses: 1) induction of acute colitis 
in BALB/c mice results in regional differences in colon inflammation, affecting analysis 
of the model; and 2) TACE inhibition will improve the disease state of DSS-induced 
colitis in mice.  Colitis will be induced in BALB/c mice through consumption of 5% DSS 
for 7 days.  TACE inhibition will be accomplished with twice daily intraperitoneal 
injections of the TACE inhibitor DPC-333.  Effect of TACE inhibition will be performed 
through systemic and local analysis of the colon.  Disease activity will be assessed with 
established parameters, including bodyweight loss, rectal bleeding, presence of diarrhea, 
and colon length.  Concentrations of IL-1β, IL-6, IL-10, and TNFα cytokines will be 
quantified in whole unstimulated plasma.  The local site of tissue injury in the colon will 
be evaluated through a regional analysis.  Cytokines will be quantified in proximal, 
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middle, and distal colon tissues.  MPO concentration will be quantified in the proximal 
and distal colons. Proximal, middle, and distal regions of the colon will be investigated to 
determine variation in cytokine concentration.  
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MATERIALS AND METHODS 
 
Animals and Induction of Colitis 
Animal care followed the Missouri State University guidelines for 
experimentation with animals and was approved on April 28, 2014 (ID# 13-015.0) by the 
Institutional Animal Care and Use Committee of Missouri State University.  Acute colitis 
was induced in male BALB/c mice by supplementing drinking water 5% DSS 
weight/volume and allowing mice to drink ad libitum for 7 days.  Administration of 5% 
DSS for 7 days is known to produce a model of severe acute inflammation in BALB/c 
mice (Kitajima et al., 2000).  The 5% DSS water was replaced with fresh DSS solution 
every two days.  
 
Dosing of DPC-333 
DPC-333 was solubilized in 25 mM citric acid (CA) saline at 1 mg DPC-333 per 
1 mL CA saline.  In a previous study, DPC-333 was solubilized with CA saline (Kim et 
al., 2008).  Qualitative solubility tests were performed to determine appropriate CA 
concentration.  DPC-333 was administered at 10 mg DPC-333 per 1 kg bodyweight by 
intraperitoneal (IP) injections of 1mg/mL DPC-333.  Pharmacokinetics and 
pharmacodynamics of DPC-333 were investigated by Qian et al., and 10 mg/kg 
bodyweight IP injection was found to effectively block TACE activity and production of 
sTNFα in vivo (Fig. 7) (Qian et al., 2007).  Fresh DPC-333 CA saline was made every 4 
days and stored at 4º C. 
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Figure 7. Dose-Dependent Inhibition of sTNFα Production In-Vivo. Dose-dependent 
TNFα inhibition with DPC-333 was determined with male BALB/c mice challenged with 
10 μg/mouse LPS IP injection.  Plasma sTNFα concentrations of IP (solid line) and oral 
(dotted line) doses of DPC-333 were compared to vehicle control to determine percent 
inhibition of sTNFα release (Qian et al., 2007). 
 
Study Design  
Two cohorts of 10 and 11 mice were used in this study.  Two control groups and 
two disease groups were generated to account for the two independent variables of 
drinking water with or without DSS and injection of DPC-333 or vehicle. Therefore, the 
four groups generated included: 1) H2O + vehicle, 2) H2O + inhibitor, 3) DSS + vehicle, 
4) DSS + inhibitor (Fig. 8).  The mice received twice daily IP injections of DPC-333 (10 
mg/kg bodyweight) or an equivalent volume of vehicle (25 mM CA saline).  DSS was 
administered for 7 days before tissue collection under isoflurane and animal sacrifice 
with isoflurane overdose and cervical dislocation.  Food and water consumption were 
monitored and clinical scoring parameters of the disease activity index were evaluated 
daily.  
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Figure 8. Study design. Two control groups and two disease groups were generated by 
consumption of water only or 5% DSS treated drinking water for seven days (days 0-7).  
One control group and one disease group received twice daily 1 mg/kg bodyweight 
injections of DPC-333 (groups 2 and 4) and the other received an equivalent volume of 
25 mmol citric acid saline vehicle injections (groups 1 and 3).  Bodyweight, food and 
water consumption, and clinical scoring were recorded daily.  
 
Disease Activity Index (DAI) Methodology and Scoring 
Animals were observed twice daily for body weight, water/food consumption, 
morbidity, stool consistency, and the presence of gross blood in feces and at the anus. 
DAI was calculated by assigning well-established and validated scores for parameters 
analogous to the clinical presentation of human IBD (Cooper et al., 1993).  
The DAI was calculated as the sum of DAI scores resulting in the total DAI score 
ranging from 0 (unaffected) to 12 (severe colitis) (Table 1).  Score parameters included 
weight loss (0 point = none, 1 point = 1–5% weight loss, 2 points = 5–10% weight loss, 3 
points = 10–15% weight loss and 4 points- more than 15% weight loss, , -1 point = 1–5% 
weight gain, -2 points = 5–10%), stool consistency/diarrhea (0 points = normal, 2 points 
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= loose stools, 4 points = watery diarrhea), and bleeding (0 points = no bleeding, 2 = 
slight bleeding, 4 points = gross bleeding).   
 
Table 1. Clinical Scoring Parameters and Scoring Guide of Disease Activity Index 
Determination.  Disease Activity Index (DAI) was calculated as a sum of clinical scoring 
parameters including percent bodyweight change, stool consistency, and bleeding.  
 
 
 
Range Score 
Percent 
Bodyweight 
Change 
5-10% Gain -2 
1-5% Gain -1 
0 0 
1-5% Loss 1 
5-10% loss 2 
10-15% loss 3 
>15 % loss 4 
   
Stool 
Consistency 
normal 0 
loose 2 
diarrhea 4 
   
Bleeding 
none 0 
slight 2 
gross 4 
 
 
Blood and Tissue Sample Collection 
Cardiac blood samples and colon specimens were collected from anesthetized 
mice under isoflurane.  Tissue samples were snap frozen in liquid nitrogen and stored at -
80oC.  Blood samples were obtained via heart stick with heparinized syringe.  Plasma was 
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separated by centrifugation at 4oC at 16.2 relative centrifugal force (RCF) for 10 minutes 
and stored at -80oC.  Prior to freezing, colon samples were cleared of fecal matter with 
ice-cold saline and dissected to generate separate segments for regional analysis of 
cytokine and MPO concentrations (Fig. 9).    
 
 
Figure 9. Colon Dissection Map and Regional Analysis.  The large intestine was removed 
under isoflurane anesthesia and sectioned into proximal, middle, and distal regions.  Each 
region was further divided into tissue samples for either MPO or cytokine analysis.  
 
Tissue Homogenization 
Tissue samples for both MPO and cytokine analysis were homogenized following 
suggested protocol supplied by Millipore (cytokine quantification kit) and within Hycult 
guidelines (MPO quantification kit).  While kept frozen atop ceramic cooled with liquid 
nitrogen, colon tissue samples were massed and broken into approximately 50 mg pieces.    
Lysis buffer cocktail was added to each sample, at 20 μL cocktail per 1 mg tissue (e.g. 50 
mg tissue/1000μL cocktail).  The lysis buffer cocktail included Tris-lysis buffer with 
1:100 protease inhibitor cocktail (Sigma-Aldrich P8340). Homogenization of tissue 
samples was performed with surgical scissors, and introduction of air bubbles was 
avoided. Samples were centrifuged at 16.2 RCF for 10 minutes at 4oC and supernatant 
removed.  Analysis of MPO and cytokine portions of colon tissue, aliquots of sample 
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were made to provide sample for assay and protein quantification without unnecessary 
freeze-thaw cycles. All tissue samples underwent 3 cycles of freeze-thaw: 1) whole tissue 
removal from animal; 2) homogenization; and 3) analysis (total protein, cytokine, or 
MPO quantification). 
 
Pierce Bicinchonicic Acid Assay 
Prior to cytokine or MPO quantification, total protein of each sample was 
determined with bicinchonicic acid (BCA) assay – a colorimetric two-component assay 
measuring reduction of Cu+2 to Cu+1 by proteins in an alkaline environment.  Standards of 
bovine serum albumin (BSA) were generated with 1:2 serial dilution of 1200 μg/mL BSA 
in phosphate buffered saline (PBS).  Samples were included in the assay at1:40 dilutions 
of sample:PBS, and were ran in duplicate.  Working reagent was generated by mixing of 
proprietary reagents A and B at 50:1. Standards and samples were added to 96-well plate, 
followed by working reagent with multichannel pipette (100μL each).  Plates were 
incubated at room temperature for 1 hour with agitation. Absorbance was read on 
SpectraMax Paradigm Multi-Mode Detection Platform at 562 nm.   
Standard curve analysis was performed with GraphPad Prism 6 graphing 
software.  Curve fit was produced with 4-parameter non-linear regression analysis and 
assay sample protein values were interpolated from the standard curve.  Central variance 
(CV) of duplicate assay samples was determined, and samples with CV greater than 20% 
were rejected.  Total protein of original tissue homogenate were calculated through 
multiplying assay total protein value by the dilution factor (40x).  
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Cytokine Quantification 
For plasma and proximal, middle, and distal colon tissue homogenates, 
concentrations of inflammatory mediators IL-1β, IL-6, IL-10, and TNFα were quantified 
with the Luminex MagPix multiplex system (Luminex Corporation; Austin Texas) and 
MilliPlex Mouse Cytokine/Chemokine Magnetic Bead Panel Kit (EMD Millipore; 
Billerica, Massachusetts).  The MilliPlex kits provide magnetic bead microspheres 
conjugated with bead-specific antibodies for use in a multiplex sandwich immunoassay 
similar to the enzyme-linked immunosorbent assay (ELISA) concept of protein 
quantification (Luminex, 2011).  However, unlike traditional ELISA assays, where the 
analyte-specific primary antibody is conjugated to a 96-well plate, the primary antibody 
is conjugated to magnetic, fluorescent beads (Fig. 10).  The analyte of interest is captured 
by the primary antibody during incubation with the sample.  The bead-antibody-analyte 
construct is incubated with a biotinylated, analyte-specific detection antibody, generating 
an immunoassay sandwich similar to traditional ELISA techniques.  Finally an incubation 
with a streptavidin-phycoerythrin (PE) conjugate is performed.  The streptavidin protein 
strongly interacts with biotin to anchor the PE conjugate to the immunoassay construct.  
PE is a fluorescent protein complex that functions as the reporter.  
The MagPix system is a LED-based system that detects individual bead identity 
through interrogation at 635nm and identification of bead-specific fluorescence (Fig. 11).  
Simultaneously, the PE fluorescent label of the immunoassay sandwich is interrogated 
with a green LED at 525 nm and fluorescence intensity is quantified.  In this manner, the 
MagPix system is capable of identifying bead/analyte type and the fluorescence intensity 
of conjugated analyte to the bead. Median fluorescence intensity (MFI) for each 
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bead/analyte type are then used to interpolate assay sample concentration from a standard 
curve.    
 
 
 
Figure 10.  MilliPlex Magnetic Bead Panel Kit for Multiplex Immunoassay Protein 
Quantification. The kit consists of a primary (1o) antibody conjugated to a magnetic bead.  
Bead fluorescence values are specific to the 1o antibody, and therefore also to the analyte 
of interest.  Incubation of the construct with sample is performed to capture the respective 
analyte.  Next, a subsequent incubation is performed to conjugate the construct to a 
biotinylated secondary (2o) antibody. A final incubation with a streptavidin-phycoerythrin 
(SV + PE) construct anchors the fluorescent PE molecule to the biotin of the 2o antibody, 
completing the construct.  
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Figure 11.  Luminex xMAP Technology and MagPix Multiplex System.  The Luminex 
MagPix is an LED-based fluorescent detection system for protein quantification. 
Magnetic, antibody-conjugated beads are passed through a magnetic capture field and 
identified with 635 nm excitation LED. Prior to assay, beads incubated with an analyte of 
interest are “sandwiched” with a reporter antibody.  During magnetic capture, the reporter 
is excited with a 525 nm LED.  By combining a range of bead fluorescence values and 
multiple primary analyte antibodies, the multiplex system is capable of identifying and 
quantifying multiple analytes simultaneously (EMD, 2015).   
 
For IL-1β, IL-6, IL-10, and TNFα quantification, 25 μL of whole, undiluted 
plasma and colon tissue homogenate samples diluted to 2-5 μg/mL were analyzed.  
Standards were generated from serial dilution of 10,000 pg/mL reconstituted Mouse 
Cytokine Standard, resulting in 6 standards down to 3.2 pg/mL.  Experimental and 
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standard samples were incubated overnight with antibody conjugated beads (25μL).  Tris 
lysis buffer was used as background matrix with tissue homogenate assays, and serum 
matrix was used as background with the plasma assay.  The samples were then 
biotinylated with a detection (secondary) antibody for one hour, and finally incubated for 
one hour with a streptavidin-phycoerythrin conjugate (reporter).  Standard, control, and 
experimental samples were run in duplicate.  Assay results of samples with greater than 
20% coefficient of variation between the duplicate wells were rejected.  Standard curve 
analysis was performed with Milliplex Analyst software.  Curve fit was produced with 5-
parameter non-linear regression analysis and assay sample protein values were 
interpolated from the standard curve.  Results of assays with tissue homogenate were 
normalized to total protein of the original tissue homogenate, previously determined by 
the BCA assay.  Prior to performing any assay, performance verification and calibration 
was performed with Millipore calibration (MPX-CAL-K25) and performance verification 
(MPX-PVER-K25) kits (EMD Millipore; Billerica, Massachusetts) to ensure optimal 
output.  
 
MPO Quantification 
Hycult Biotech HK210 mouse MPO ELISA kit was used to quantify MPO in 
tissue homogenates of proximal and distal colon segments.  The kit supplied strips of 
microtiter wells coated with primary antibody, and 100μL of diluted standard and 
samples were incubated for one hour in the wells.  Captured MPO was then incubated 
with biotnylated tracer antibody (second antibody) for one hour. Finally, a one hour 
incubation with a streptavidin-peroxidase conjugate (third antibody) was performed. The 
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oxidative capacity of the peroxide conjugate was determined through reduction and 
colorimetric change in tetramethylbenzidine (TMB) solution after a 30 minute 
incubation. The reduction of TMB was stopped with the addition of oxalic acid.   
Mouse MPO standards were generated through serial dilution of a 100 pg/mL 
stock solution, producing 7 standards from 100 to 1.6 pg/mL.  Standard curve analysis 
was performed with GraphPad Prism 6 graphing software.  Curve fit was produced with 
5-parameter non-linear regression analysis and assay sample protein values were 
interpolated from the standard curve.  Central variance (CV) of duplicate assay samples 
was determined, and samples with CV greater than 20% were rejected.  Total MPO levels 
of original tissue homogenate were calculated through normalizing assay MPO value by 
the total protein of the sample.   
 
Statistics 
Results from my study were analyzed with independent t-tests between group 
means and were performed with GraphPad Prism analysis software.  Analysis for 
successful development of colitis was performed with t-tests between water control and 
DSS colitis groups receiving vehicle control injections (group 1 vs group 3).  Effect of 
the inhibitor (DPC-333) was determined through t-test between DSS colitis groups 
receiving either vehicle control or DPC-333 injections (group 3 vs group 4).  F-Test of 
equality of variances was used to determine if the variances between groups were 
significantly different (p < 0.05).  For groups without equal variance, Welch’s correction 
was performed.  For group 3 (DSS/vehicle injection), a one-way between-subjects 
ANOVA was performed to compare the regional effect of DSS administration on IL-1β 
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and IL-6 concentrations in proximal, middle, and distal regions of the colon.  Equal 
variance was verified with Brown-Forsythe test (p > 0.05).  Post hoc comparisons 
between group means using the Tukey test were performed if the ANOVA indicated a 
significant regional effect on cytokine concentration.   
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RESULTS 
 
Clinical Presentation of 5% DSS Colitis 
To evaluate successful development of colitis, groups 1 and 3 were compared 
with an independent t test (Group 1: H2O /Vehicle Injection; Group 3: 5% DSS/Vehicle 
Injection).  Effect of TACE inhibition during DSS-induced colitis was evaluated with an 
independent t test between groups 3 and 4 (Group 3: 5% DSS/Vehicle Injection; Group 4: 
5% DSS/DPC-333 Injection).   Administration of 5% DSS for 7 days significantly 
increased the disease activity index (DAI) (p < 0.0001) (Fig. 12).  TACE inhibition 
reduced DAI by 12%, although this reduction was not significant (p = 0.1031).    
 
 
Figure 12. TACE Inhibition and Average Disease Activity Index during Development of 
Colitis.  DAI quantified through evaluation and scoring of bodyweight loss, rectal 
bleeding, and diarrhea as described in the text. Values are group means ± SEM; ***p < 
0.0001. 
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The contributing parameters to DAI were analyzed with the same methodology.  
DSS administration induced significant bodyweight loss on day seven (p < 0.0001) (Fig. 
13).  DSS drinking mice also receiving TACE inhibitor exhibited lower bodyweights on 
day seven (-2.4%), although this difference was not significant (p = 0.3961).   DSS 
consumption significantly increased gross bleeding at the rectum and clinical bleeding 
score (p < 0.0001) (Fig.14).  TACE inhibition during colitis significantly reduced gross 
rectal bleeding and bleeding clinical score on day seven (p = 0.0113).  Watery stools and 
diarrhea were increased with DSS consumption and stool consistency score was 
significantly increased on day seven (p < 0.0001) (Fig. 15).  Stool consistency scores 
were significantly improved on day seven by administration of TACE inhibitor 
(p = 0.0014).  Semi-quantitative estimates of daily food and water consumption indicate 
healthy consumption of food and water (Fig. 16 and 17).   
 
 
Figure 13. TACE Inhibition and Average Bodyweight during Development of Colitis.  
Values are group means ± SEM; **p < 0.001 (Group 1:Group 3).  
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Figure 16. TACE Inhibition and Food Consumption during Development of Colitis.  
Semi-quantitative estimates of daily food consumption. Values are group means ± SEM. 
 
 
 
 
Figure 17. TACE Inhibition and Water Consumption during Development of Colitis. 
Semi-quantitative estimates of daily food consumption. Values are group means ± SEM. 
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DSS administration resulted in significantly decreased colon lengths (p <0.0001) 
(Fig. 18).  Injections of TACE inhibitor decreased colon lengths further, although the 
difference was not significant.  For example, the colons of Group 4 (DSS/DPC-333) 4.7% 
shorter than Group 3 (DSS/Vehicle), however, the reduction was not significant 
(p=0.2967). The clinical results of 5% DSS administration for seven days with and 
without administration of the TACE inhibitor DPC-333 are summarized in Table 2.   
 
 
Figure 18. TACE Inhibition and Average Colon Length during Development of Colitis.  
Excised colon organs were measured from the ileocecal junction to the end of the rectum. 
Values are group means ± SEM; *p < 0.0001. 
 
 
 
Plasma Cytokine Levels 
Systemic inflammatory spillover from the colon tissue was evaluated through 
multiplex immunoassay quantification of IL-1β, IL-6, IL-10, and TNFα levels in whole 
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consumption (p = 0.0676, 0.7551, 0.8510, and  0.1307, respectively).  Administration of 
DPC-333 during development of colitis did not significantly alter plasma levels of IL-1β, 
IL-6, or IL-10 (p = 0.5153, 0.3847, and 0.4768, respectively).  Between the DSS groups 
(groups 3 and 4), plasma TNFα levels were significantly reduced by 7.9% with injections 
of TACE inhibitor (p = 0.0245) (Fig. 19D). 
 
Table 2. Statistical Analysis of Clinical Parameters in Colitis Development.  Results of 
independent t-test of clinical parameter on day 7 of 5% DSS.  Equal variance was verified 
with F test to compare variances (p < 0.05).  Group 1 (G1): H2O +Vehicle injection; 
Group 3 (G3): DSS+Vehicle Injection; Group 4 (G4): DSS+DPC Injection.  Values are 
expressed as group means ± SEM. 
 
 G1  
(n = 5) 
G3 
(n = 5) 
G4 
(n = 6) 
p value 
Parameter G1 vs G3 G3 vs 
G4 
DAI -0.4 ± 0.6 8.4 ± 1.0 7.4 ± 0.8 < 0.0001 0.1031 
Ave Bodyweight (g) 24.8 ± 1.4 20.9 ± 0.8 20.4 ± 1.0 0.0006 0.3961 
Bleeding Score 0.00 ± 0.0 2.80 ± 0.8 1.67 ± 0.33 < 0.0001 0.0113 
Diarrhea Score 0.00 ± 0.0 2.80 ± 0.5 1.67 ± 0.33 < 0.0001 0.0014 
Colon Length 11.2 ± 0.2 7.5 ± 0.5 7.2 ± 0.4 < 0.0001 0.2967 
 
 
Colon Cytokine Levels 
Regional Effect of DSS Colitis on Colon Cytokine Levels. The effect of 5% DSS 
administration for 7 days on regional colon cytokine concentrations was evaluated 
through an independent t-test between cytokine concentrations of groups 1 and 3 (Group 
1: H2O /Vehicle Injection; Group 3: 5% DSS/Vehicle Injection) (Fig. 20).  A trend of 
DSS administration increasing cytokine concentration of each analyte (IL-1β, IL-6, IL-
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groups 3 and 4 for each cytokine (Group 3: 5% DSS/Vehicle Injection; Group 4: 5% 
DSS/DPC-333 Injection).  No significant difference was observed for any of the analytes 
in any of the colon regions.  The largest effect of TACE inhibition was observed in the 
distal colon, where DPC-333 injections during colitis development increased IL-10 
concentrations by 81.7% (p = 0.0746).  Administration of DPC-333 consistently 
decreased colon TNFα levels in the proximal, middle, and distal regions, although this 
decrease was not significant (Table 3). 
 
 
Figure 21. Effect of TACE Inhibition on Regional Cytokine Concentration in the Colon.  
Tissue concentrations of (A) IL-1β, (B) IL-6, (C) IL-10, and (D) TNFα were quantified 
from proximal, middle, and distal regions of the colon after 7 days of 5% DSS. Groups 
received 2x daily IP injections of either 10mg/kg BW DPC-333 or equivalent volume of 
vehicle (25mMol citric acid saline).  Values are group means ± SEM.  
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Table 3. TACE Inhibition and Percent Difference in TNFα Levels. Percent difference in 
TNFα levels between Group 3 (DSS+Vehicle injection) and Group 4 (DSS+DPC-333 
injection) in plasma, and proximal, middle, and distal colons (P Col, M Col, and D Col).  
Results are independent t-test p values of TNFα concentrations on day 7 of 5% DSS.  
Equal variance was verified with F test to compare variances (p < 0.05) and Welch’s 
Correction performed if p < 0.05.  Values are expressed as group means ± SEM. 
 
 
  
Plasma P Col M Col D Col 
TNFα 
Concentration 
(pg/mg tissue) 
 
Group 3 
13.19 ± 
0.34 
6.29 ± 
2.00 
1.60 ± 
0.71 
5.82 ± 
0.66 
Group 4 
12.15 ± 
0.17 
4.69 ± 
0.97 
 1.22 ± 
0.23 
4.22 ± 
0.90 
       
  
% Difference -7.8 -25.4 -23.6 -27.6 
p value 0.0245 0.445 0.633 0.230 
 
 
Overview of Colon Cytokine Levels during DSS Colitis and TACE Inhibition 
Concentrations of individual cytokines in the proximal, middle, and distal colons 
of groups 1-4 are graphically overviewed in Fig. 22 and 23.  In the absence of statistical 
significance between groups, trends of cytokine levels can be observed. Without 
stimulation from DSS (Groups 1 and 2), basal levels of IL-1β, IL-10, and TNFα may be 
elevated in the proximal and distal colons.  In contrast, Il-6 concentrations may increase 
in more distal portions of the colon tissues.  A trend of increased cytokine concentration 
in the distal colon with consumption of DSS can be observed.   The highest IL-1β, IL-6, 
and IL-10 concentrations are observed in the distal colon. Regional TNFα release did not 
follow this trend, as proximal and distal levels were elevated.   
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Colon Tissue Myeloperoxidase Levels 
To evaluate neutrophil recruitment to the colon in response to inflammation, MPO 
concentration in colon tissue was quantified (Fig. 24).  ELISA assays were performed to  
 
 
Figure 24. Effect of DSS Colitis and TACE Inhibition on Colon MPO Concentration.  
MPO concentration in proximal and distal regions of colon tissue after 7 days of 5% DSS 
(or H2O control).  Groups received 2x daily IP injections of either 10mg/kg BW DPC-
333 or equivalent volume of vehicle (25mMol citric acid saline).  Values are group 
means ± SEM. 
 
quantify MPO levels in tissue homogenate from proximal and distal colon regions.  
Effect of 5% DSS for 7 days was determined through comparison between groups 1 and 
3 (Group 1: H2O /Vehicle Injection, Group 3: 5% DSS/Vehicle Injection) and effect of 
DPC-333 injections was determined through comparison of groups 3 and 4 (Group 3: 5% 
DSS/Vehicle Injection; Group 4: 5% DSS/DPC-333 Injection).  Consumption of 5% DSS 
p = 0.4047  
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Effect of DSS Colitis and TACE Inhibition  
on Colon MPO Concentration 
Group 1: H2O/Veh (Prox n=5; Dist n=5) Group 2: H2O/Inh (Prox n=5; Dist n=3)
Group 3: DSS/Veh (Prox n=4; Dist n=3) Group 4: DSS/Inh (Prox n=6; Dist n=5)
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did not significantly change MPO levels in the proximal or distal colon. TACE inhibition 
during the development of colitis did not significantly change MPO concentration in 
proximal or distal colons. Although the results of MPO quantification are not significant, 
DPC-333 administration during the development of colitis (group 4) produced a large 
percent increase of MPO (272.5%) in the proximal colon (Table 4).  In contrast, the distal 
colon displayed increased MPO concentration with administration of 5% DSS (434.9%) 
and this increase was diminished with DPC-333 administration (-44.2%).  
 
Table 4. Effect of 5% DSS and TACE Inhibition on Colon MPO Concentrations. Percent 
difference in MPO levels between groups 1:3 and groups 3:4.  Results are independent 
t-test p values of TNFα concentrations on day 7 of 5% DSS.  Equal variance was verified 
with F test to compare variances (p < 0.05) and Welch’s Correction performed if p < 
0.05.   
 
 
G1(n = 5) G3(n = 5) G4(n = 6) 
% Difference 
(p value) 
Region G1 vs G3 G3 vs G4 
Proximal 21.0 ± 8.4 33.0 ± 15.2 123.0 ± 50.4 
57.4 
(0.405) 
272.5 
(0.148) 
Distal 12.7 ± 2.9 67.8 ± 34.9 37.8 ± 16.3 
434.9 
(0.256) 
-44.2 
(0.487) 
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DISCUSSION 
 
Clinical Evaluation of DSS Colitis and Effect of TACE Inhibition 
Administration of 5% DSS for seven days in BALB/c mice produced a disease 
model consistent with experimental colitis literature (Chassaing et al., 2014).  
Bodyweight loss, rectal bleeding, incidence of diarrhea were all significantly increased 
with high confidence.  Additionally, colon lengths of colitis mice were significantly 
shortened, also consistent with the DSS colitis model.  TACE inhibition did not improve 
the overall disease state of 5% DSS colitis for seven days.  Although a significant 
reduction in diarrhea and bleeding scores was observed, bodyweight loss was increased 
in the TACE inhibition experimental group.  As a result, overall disease activity index 
(DAI) was not improved.  Additionally, TACE inhibition did not attenuate shortened 
colon lengths in the DSS groups, instead resulting in a further non-significant decrease in 
length.  Estimates of average food and water consumption by the animals indicate all 
groups continued to consume food and water throughout the trial.  Abrupt decrease in 
food and water consumption leads to quick onset of bodyweight loss and would have 
impacted the DAI results.  However, no such effect was observed in my study.  
 
Effect of DSS on Inflammatory Cytokines 
Administration of 5% DSS for 7 days did not significantly alter the plasma 
concentrations of IL-1β, IL-6, IL-10, or TNFα.  This indicates the local inflammatory 
response had limited spillover into the systemic circulation.  The blood samples were 
obtained from the heart, and therefore may not be representative of blood prior to 
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metabolic action of the liver.  Samples from the hepatic portal vein may have increased 
levels of the inflammatory cytokines which are metabolized and reduced in the liver.  
Regional analysis of cytokine concentration after 7 days of 5% DSS 
administration implicate the distal colon as the most impacted region.  Distal colon IL-10 
and TNFα were significantly increased compared to non-DSS controls.  Large fluctuation 
of distal colon IL-1β and IL-6 concentrations were also observed, although due to high 
variance, these results were not significant.   
A one-way between-subjects ANOVA was performed on group 3 (DSS/vehicle 
injection) to compare the regional effect of DSS administration on IL-1β and IL-6 
concentrations in proximal, middle, and distal regions of the colon (Table 5). There was a 
significant effect of DSS administration on IL-6 concentration (p < 0.05) between the 
colon regions [F(2, 10) = 4.136, p = 0.0491].  There was not a significant effect on 
regional IL-1β concentrations [F(2, 11) = 0.4983, p = 0.2346].   Post hoc comparisons 
between group means using the Tukey test indicated the mean IL-6 concentrations 
between the proximal and distal colons (mean difference = -1655, SE of difference = 
575.9) were significantly different (p = 0.0402) (Table 5C).  This ANOVA of regional 
IL-6 concentration during DSS colitis suggests IL-6 concentrations are higher in the 
distal colon.  This analysis is not ideal because the cytokine concentration is not 
compared to basal level concentrations in a non-DSS control.  However, because the 
clinical data indicates successful induction of colitis, the ANOVA analysis serves as 
limited evidence further implicating the distal colon as the more affected region during 
DSS-induced colitis, particularly with regard to IL-6 concentration.   
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Table 5.  ANOVA and Post Hoc Results of Colon IL-1β and IL-6 Concentrations in the 
Colon.  Analysis of variance of IL-1β (A) and IL-6 (B) concentrations in proximal, 
middle, and distal colon regions after 7 days of 5% DSS administration was performed on 
group 3 (DSS/Vehicle injection).  Post hoc comparisons (C) were made using Tukey’s 
multiple comparisons test.  
 
 
A)  IL-1B ANOVA Results 
Comparison df F Sig 
Between Groups 2 1.659 p = 0.2346 
Within Groups 11 
  Total 13 
    
B)  IL-6 ANOVA Results 
Between Groups 2 0.0491 p = 4.136 
Within Groups 10 
  Total 12 
    
C)  IL-6 Post Hoc 
 Mean diff. SE of diff. Adjusted p Value 
Proximal vs Middle -682.2 575.9 0.488 
Middle vs. Distal -1655 575.9 0.0402 
Distal vs. Middle -973 607 0.2889 
 
 
Differences in relative levels of individual cytokines in the colon (e.g. IL-6 vs 
TNFα)  corresponds to previous investigation quantifying mRNA expression of IL-1β, 
IL-6, and TNFα (Yan et al., 2009).  These data indicate a 23-fold increase in colon IL-6 
expression in C57BL/6 mice, while TNFα expression increased 9-fold (Fig. 25).   
 
58 
 
Figure 25.  Colon Cytokine Production during 3.5% DSS in C57BL/6 Mice.  Mice were 
administered 3.5% DSS for five days, followed by regular water after day five.  Real time 
PCR was used to determine mRNA expression of inflammatory cytokines in colon tissue 
(Yan et al., 2009). 
 
Additionally, the relative levels of individual cytokine concentrations in my study 
(TNFα < IL-1β < IL-6) also correspond to cytokine concentrations derived from 
mononuclear cell extracts in UC patients (Reinecker et al., 1993) (Fig. 26).  Because of 
elevated IL-6 concentration relative to other cytokines, inhibition of IL-6 during 
pathologic inflammation has been investigated previously.  Tocilizumab (a monoclonal 
antibody against IL-6) is currently used to treat rheumatoid arthritis (Smolen et al., 2008). 
However, direct inhibition of IL-6 during colitis may not be advantageous due to an 
important role of IL-6 in regenerating intestinal epithelium through the signal transducer 
and activator of transcription 3 (Grivennikov et al., 2009).  Clinical trial of Tocilizumab 
administration during active CD was effective in reducing disease severity. However, 
only 2 of 10 patients experienced disease remission (Ito et al., 2004).  Additionally, 
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Tocilizumab may increase risk for diverticulitis, relative to other rheumatoid arthritis 
treatments (Gout et al., 2011).  Because of these concerns, Tocilizumab is currently 
avoided as treatment in rheumatoid arthritis when IBD conditions are already present. 
 
 
Figure 26. Inflammatory Cytokine Concentrations in Mononuclear Cells from UC Patient 
Colon Tissues.  Lamina propria mononuclear cells were isolated from colon tissue 
biopsies in healthy and UC patients and cultured for 48 hours.  Samples from UC patients 
were taken from involved (inv.) and non-involved (non-inv.) areas of mucosal 
inflammation. The samples were either unstimulated (white bars) or cultured with 
pokeweed mitogen (black bars), an agonist of toll-like receptors and activator of NF-κB 
(Reinecker et al., 1993). 
 
Effect of TACE Inhibition on Inflammatory Cytokine Concentrations  
A significant reduction in plasma sTNFα levels was observed with twice daily IP 
injections of DPC-333 (10mg/kg bodyweight) during the 7 day development of 5% DSS 
colitis.  This result is indicative of systemic inhibition of TACE activity and is evidence 
of biologically active circulating levels of DPC-333. However, the activity of DPC-333 
was not significantly extended to the colon tissue.   Although there was a trend for 
reduction in sTNFα during the development of DSS colitis, these decreases were not 
statistically significant.  
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The largest impact DPC-333 administration had on the colon tissue cytokines was 
observed in the IL-10 concentrations of the distal colon (81.7% increase, p = 0.0746). 
Conclusions from this observation are speculative.  Several studies using IL-10 knockout 
mice have implicated this cytokine as protective against colitis development (Kühn et al., 
1993; Marlow et al., 2013; Scheinin et al., 2003).  However, IL-10 expression also 
increases proportionally with increasing inflammatory cytokine signaling and NF-κB 
transcriptional activity.  Because there was not an observable benefit to the DAI during 
TACE inhibition, a conclusion cannot be made that increased IL-10 levels are indicative 
of an anti-inflammatory effect by TACE inhibition.  
 
Overview of Colon Cytokine Concentrations 
The graphical overview of each cytokine (Fig. 22 and 23) highlights the role of 
the distal colon in the development of colitis in this model.  The highest concentrations of 
IL1β, IL-6, and IL-10 were consistently observed in the distal colons of the DSS 
experimental groups (groups 3 and 4).  An interesting exception to this trend was 
observed in the proximal colon levels of TNFα.  Basal and DSS-stimulated TNFα 
concentrations of the proximal colon were more similar to the distal colon than the 
middle region.  However, increased TNFα levels from DSS administration were only 
significant in the distal colon, also implicating the distal colon as the most affected 
region.   
If the distal colon is the primary site of inflammation in this DSS colitis model, 
then anti-inflammatory effects on the cytokine expression profile in this region would 
likely be the most beneficial.  TACE inhibition, although non-significant, increased the 
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levels of IL-1β and IL-6, suggesting a pro-inflammatory effect.  Coupled with lack of 
improvement in the clinical parameters from TACE inhibition, increased IL-10 in the 
distal colon from TACE inhibition cannot be concluded as an anti-inflammatory effect of 
TACE inhibition.   
Despite an overall trend (non-significant) of decreased colon TNFα levels with 
TACE inhibition, my evidence suggests other pro-inflammatory compensatory cytokine 
signaling may compensate for any reduced TNFα levels from providing a beneficial 
clinical effect.  The bioavailability of IP injected DPC-333 to the colon tissue may be 
limited, and therefore not effective in reducing TNFα levels.  Increasing the duration of 
TACE inhibition prior to DSS administration may not improve the outcome, as inhibition 
of TNFα with Infliximab during the development of DSS colitis is accomplished with 
rapid onset of TNFα inhibition.  For example, three days of 10mg/kg bodyweight IP 
injection of Infliximab at the onset of DSS administration is effective at reducing clinical 
parameters of colitis after seven days of DSS consumption (Qiu et al., 2011).  Therefore, 
IP injections of DPC-333 in conjunction with DSS administration should reduce TNFα 
levels if it is capable reaching the colon tissues.  If TACE inhibition with DPC-333 was 
more effective in reducing colon TNFα, there may have been an improved response 
during development of DSS colitis.  
 
Effect of DSS on Colon Neutrophil Recruitment as Determined by MPO Levels 
On day seven of 5% DSS administration, MPO concentrations were not 
significantly increased in either the proximal or distal colon (Fig. 24).  However, MPO in 
the distal colon was 434.9% greater (p = 0.2561) and increasing sample size in future 
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study may provide significance by reducing standard deviation from the mean (Table 4).  
The percent elevation in proximal colon MPO was much less (57.4%, p = 0.4047).  A 
more pronounced increase of MPO levels in the distal colon during appears to correlate 
with increased cytokine concentrations in the distal colon.  The MPO data suggests 
neutrophil recruitment predominately impacts the distal colon in this model of colitis.  
 
Effect of TACE Inhibition on Colon MPO Levels during Development of Colitis 
The most unexpected data of this study can be observed in the effect of TACE 
inhibition on MPO levels in the proximal region (Fig. 24).  In the distal colon, TACE 
inhibition reduced MPO concentration of the DSS experimental groups (groups 3 and 4) 
by 44.7% (Table 4).  Although this decrease was not significant (p = 0.230), it could be a 
result of decreased L-selectin cleavage by TACE, and impaired emigration of neutrophils 
out of the capillaries and into the colon tissue. Surprisingly, TACE inhibition during 
development of DSS colitis increased MPO concentrations by 434.9% in the proximal 
region for unexpected reasons. The data from this study suggests TACE inhibition may 
increase sensitivity or susceptibility to neutrophil recruitment to the proximal colon in 
this DSS model of colitis.  
 
Conclusions 
Clinical Colitis Model and Effect of TACE Inhibition.  Current literature and 
research on chemical models of colitis in mice vary widely in multiple aspects which 
alter the disease model and findings (Melgar et al., 2005).  These parameters include type 
of inflammatory stimulus, duration and concentration of stimulus administration, and 
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strain of mouse.  Additionally, TACE inhibition studies also vary in duration of 
inhibition, timing of administration relative to induction of colitis, and specific TACE 
inhibitor used (Sharma et al., 2014).  The current study shows twice daily IP injections of 
the TACE inhibitor DPC-333 does not provide a clinically-relevant protective effect 
during the development of colitis for 7 days with administration of 5% DSS in BALB/c 
mice. Considering the potent reduction of TNFα levels during TACE inhibition in LPS 
models of sepsis and a lack of reduction in colon TNFα levels in my study, other delivery 
methods of DPC-333 may improve bioavailability to the colon and result in significant 
reduction of TNFα levels (Qian et al., 2007).    
Inhibition of TACE and effect on conditions of intestinal inflammation is a 
complex physiological process.  Chalaris et al. published work in 2010 in the Journal of 
Experimental Medicine implicating decreased TACE activity with increased 
susceptibility to DSS inflammation (Chalaris et al., 2010)..  Although complete 
disruption of TACE activity results in an unviable animal (Peschon et al., 1998), Chalaris 
et al. developed a novel method for producing mice with severely (although not 
completely) impaired TACE activity in all cells of the mouse.  Subsequently, the 
presence of soluble products from TACE sheddase activity were reduced.  For example, 
decreased levels of soluble TNFR2 were detected and these animals presented with EGF-
R and EGF-R ligand-type mutations such as eye, hair, and skin defects.  Despite these 
affects, the intestinal epithelia did not display any “overt abnormalities.”  The knockdown 
mice displayed dramatically increased susceptibility to DSS-induced inflammation and 
colitis.   A 2% DSS regimen resulted in severe weight loss and a mortality rate greater 
than 50%.  These results demonstrate increased susceptibility to DSS resulted from 
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impaired regeneration of epithelial cells in the absence of STAT3 activation by soluble 
EGF-R ligands.  
In contrast, encouraging results of TACE inhibition and a protective effect against 
colitis were recently published (Sharma et al., 2014).  The study demonstrated the ability 
of a novel TACE inhibitor (termed 11p) to improve the recovery phase of C57BL/6 mice 
from 3.5% DSS (Fig. 27).  DSS was administered for 5 days and replaced with water  
 
 
Figure 27. TACE Inhibition and Recovery from DSS Colitis.  Data reported by Sharma et 
al. demonstrating a positive effect of TACE inhibition on DSS-induced colitis in 
C57BL/6 mice.  3.5% DSS was administered for 5 days and TACE inhibitor (11p) was 
orally administered daily for 7 days.  Colon lengths were determined on day 10 (C).  
MPO activity was assayed on day 8 (D).  TACE inhibition decreased percent bodyweight 
loss (A), improved DAI (B), attenuated colon shortening (C), and decreased colon MPO 
activity (D) (Sharma et al., 2014). 
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only for subsequent days.  The TACE inhibitor 11p was orally administered daily from 
day 0 to day 7.  Through day 10 (5 days post DSS), TACE inhibition improved DSS-
induced DAI, bodyweight loss, colon lengths (day 10), and MPO activity (day 8).  In 
addition, concentration of inflammatory cytokines IL-1β, IL-6, and TNFα in the colon 
were significantly decreased on day 5.  
Regional Analysis of Colitis and TACE Inhibition.  Regional between-group 
analysis of the H2O vs 5% DSS administered mice and analysis of variance between 
colon regions indicates a disproportionate regional effect on the distal colon.  DSS 
administration altered the inflammatory cytokine concentrations profile, particularly in 
the distal region of the colon.  In support of this data, a non-significant elevation (45%) in 
MPO also occurred in the distal colon relative to the water control.  Taken together, these 
finding implicate the distal colon as the most impacted region of the colon during the 
development of DSS colitis in mice.   
This observation is clinically relevant and improves the validity of the DSS model 
of colitis, because clinical ulcerative colitis in humans also progresses in a distal to 
proximal manner along the colon.  In addition, progression of clinical human colitis from 
“left sided” to “extensive” colitis drastically alters the delivery approach and response to 
current UC treatments.  Therefore, this information is particularly relevant for the 
investigation of drug delivery methods of any current and potential pharmaceutical 
therapy to improve UC.  In addition to clinical relevance, this data impacts the study of 
DSS experimental colitis.  Whole-colon approaches investigating colitis with a DSS 
model must consider a loss of effect due to inclusion of colon tissue which is not in a 
state of inflammation.   
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The results of this study display striking similarities to DSS treatment of the 
TACE knockdown model generated by Chalaris et al.  In the TACE knockdown mice, 
although L-selectin and TNFα shedding was “completely abrogated,” DSS treated 
animals displayed increased MPO activity in the colon (Chalaris et al., 2010).  Expression 
of IL-10 and IL-11 (a member of the IL-6-type cytokine family) were also up-regulated.  
These previous results correlate well with the surprising increase of MPO of the proximal 
colon and IL-10 of the distal colon during TACE inhibition.  In addition, a lack of effect 
on clinical parameters is also explained. Charlaris et al., observed decreased soluble 
TNFR2 in the TACE knockdown model.  Preloading the tissue with TACE inhibitor may 
sensitize the cell to soluble and membrane TNFα and prevent sTNFα sequestering effects 
of soluble TNFR2 (Fig. 28). This effect would compound other pro-inflammatory effects 
of impaired epithelial regeneration from inhibited EGF signaling during TACE 
inhibition.  In contrast, oral administration of a TACE inhibitor instead of IP injection 
may allow for greater reduction in colon TNFα levels and improved recovery from DSS 
induced colitis (Sharma et al., 2014).  
Concluding Remarks and Summary. TACE inhibition did not decrease clinical 
scoring parameters or reduce concentration of inflammatory biomarkers in the colon 
during experimental colitis.  Regional analysis of the colon in the DSS colitis mouse 
model indicates a disproportionate inflammation of the distal aspect.  These data provide 
novel information to field of experimental colitis due to DSS. 
 
Limitations of Data 
These data are limited in a number of ways, primarily by sample size.  The most 
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Figure 28. Implications of TACE Inhibition and Receptor Cleavage.  In addition to 
TNFα, TACE is a principle sheddase of TNFR2.  Inhibition of TACE may increase cell 
surface TNFR and sensitize the cell to sTNFα.  Decreased receptor cleavage may also be 
pro-inflammatory as a consequence of lost neutralization of sTNF by soluble TNFR 
(Moss et al., 2008). 
 
appropriate statistical analysis of this study design would be a 2-way ANOVA to 
determine effect of the two independent variables (DSS consumption, DPC-333 
injections). However, because of small sample size, independent t tests were used to 
compare groups for induction of colitis and effect of DPC-333 injections during colitis.  
Because of this, effect of the inhibitor alone (Group 2: H2O /DPC-333 Injection) was not 
statistically analyzed.  However, TACE inhibition alone, including in the TACE 
knockdown model of Chalaris et al. has not previously presented pro-inflammatory 
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effects to date. In addition, large and non-significant percent differences are a common 
aspect of these results.  Increased sample size may provide statistical significance in a 
number of comparisons.   
The pre-clinical data is limited by lack of blinding during evaluation of the 
clinical parameters.  A previous trial with TACE inhibition during development of 3% 
DSS colitis indicated TACE inhibition would not improve clinical parameters or DAI 
(data not shown).  Because of this, blinding was omitted to increase confidence in 
administration of vehicle and DPC-333 to respective mice during twice daily injections. 
Although the bleeding and stool consistency data shows statistical significance, overall 
DAI is not reported to improve with TACE inhibition.  In future studies, if TACE 
inhibition can be tailored to positively affect the clinical parameters of the DSS colitis, 
the clinical data will need to be blinded to ensure elimination of any unforeseen potential 
bias.  Evaluation of colitis in future study would benefit from histological evaluation of 
the colon mucosa to investigate tissue morphology and impact of treatment on structure.   
The effects of TACE inhibition preloading on colon MPO are supported by the 
regional cytokine analysis.  However, much more support would have been provided 
through quantification of chemotactic factors, such as the chemokine IL-8.  Inclusion of 
chemokines in the immunoassay would have allowed evaluation of signaling received by 
circulating neutrophils to undergo the process of emigration.  The current conclusions 
hypothesized for this study would be strengthened if TACE inhibition during the 
development of colitis increased IL-8 in the proximal colons.    
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Future Study 
Long-term treatment of IBDs such as UC and CD with TACE inhibition may not 
be beneficial due to side effects from reduced cleavage of other TACE (ADAM17) 
substrates such as EGF, angiotensin converting enzyme, and amyloid precursor protein 
(Allinson et al., 2004).  This study and previous research also suggest TACE inhibition 
prior to the presence of an inflammatory stimulus may be detrimental.  The clinical 
relevance of the protective effects of TACE inhibition in acute systemic inflammation 
models with LPS challenge are unknown (Qian et al., 2007).  Preliminary data showing 
DPC-333 solubilized in 250 mM citric acid saline maintains biological activity and is 
capable of attenuating elevated plasma TNFα levels during LPS challenge (Fig. 29). 
 
 
Figure 29.  TACE Inhibition with DPC-333 in a Sepsis Model.  Preliminary data (n=2 per 
group) of 10 mg/kg bodyweight IP injection of DPC-333 solubilized in 250 mM citric 
acid saline.  DPC-333 injection was performed 1 hour prior to challenge with LPS (10 
mg/kg bodyweight).  At t = 5 hours, plasma samples were collected and TNFα quantified 
with multiplex immunoassay.  
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Effect of IP DPC-333 during LPS Challenge 
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Based upon these preliminary data and previous literature, DPC-333 appears to be 
a more effective plasma inhibitor of TACE activity such as during the onset of sepsis. 
However, DPC-333 does not appear to positively impact the local tissue response during 
acute inflammation in this model (Table 4).  If substrate-dependent inhibition of TACE is 
possible, benefit may arise from specific inhibition of sTNFα cleavage.  However, more 
research into TACE substrate recognition is needed.  If specific inhibition of mTNFα 
cleavage is possible, the possibility of cell accumulation of mTNFα and signaling effects 
would need to be investigated.   
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